This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alnara Pharmaceuticals (developing oral protein therapeutics for metabolic disorders) raised $35mm in its Series B financing led by first-time backer MPM Capital, which was joined by returning shareholders Third Rock Ventures, Frazier Healthcare, and Bessemer Venture Partners. The company will use some of the funds to help gain approval for and launch its liprotamase to treat exocrine pancreatic insufficiency, and for ongoing development of a liprotamase formulation aimed at cystic fibrosis in pediatric patients. A member of MPM will take a seat on Alnara's board.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?